partnering

News

Gilead looks beyond Trodelvy with Tubulis alliance

Gilead Sciences has shored up its antibody-drug conjugate pipeline by licensing a candidate from German biotech Tubulis in a deal worth up to $415m.

News

Orexo exits depression DTx alliance with GAIA

Four years after buying US rights to GAIA's digital therapeutic to help people with depression, Swedish drugmaker Orexo has terminated the deal.

Sales & Marketing

Veeva Summit - Chris Moore, president of Veeva Europe

A next-generation mindset: Veeva Commercial Summit 2024

Imagine a time when all your teams collaborate seamlessly. That’s what this year’s Veeva Commercial Summit posited as it commenced.

News

Daiichi Sankyo partners Alteogen on subcutaneous Enhertu

Daiichi Sankyo has signed a deal worth up to $300 million with South Korean biotech Alteogen to develop a subcutaneous version of its AstraZeneca-partnered cancer drug Enhertu.

News

Representation of Ascendis Pharma technology

Novo puts $285m into monthly GLP-1 based on Ascendis tech

Novo Nordisk has partnered with Ascendis Pharma on less frequently dosed drugs for obesity and other metabolic diseases, starting with a once-monthly GLP-1 receptor agonist.

News

Novartis pays $150m upfront for Monte Rosa degrader drug

The lengthening list of pharma alliances focused on molecular glue degraders has another entry after Novartis signed a deal with Monte Rosa Therapeutics worth up to $2.2 billion.

Gilead looks beyond Trodelvy with Tubulis alliance

Orexo exits depression DTx alliance with GAIA

A next-generation mindset: Veeva Commercial Summit 2024

Daiichi Sankyo partners Alteogen on subcutaneous Enhertu

Novo puts $285m into monthly GLP-1 based on Ascendis tech

Novartis pays $150m upfront for Monte Rosa degrader drug

Protego's $130m for amyloidosis drug, and other financings

How to meet your physicians where they are online

partnering

Editor's Picks